APLS SHAREHOLDER ALERT: Jakubowitz Law Reminds Apellis Shareholders of a Lead Plaintiff Deadline of October 2, 2023
NEW YORK, Aug. 11, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/apellis-class-action-loss-submission-form/?id=43324&from=4
The lawsuit seeks to recover losses for shareholders who purchased Apellis between January 28, 2021 and July 28, 2023.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until October 2, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Apellis Pharmaceuticals, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the design of SYFOVRE's clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original content:https://www.prnewswire.com/news-releases/apls-shareholder-alert-jakubowitz-law-reminds-apellis-shareholders-of-a-lead-plaintiff-deadline-of-october-2-2023-301898488.html
SOURCE Jakubowitz Law
Ausgewählte Hebelprodukte auf Apellis Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Apellis Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Apellis Pharmaceuticals Aktie News
Apellis Pharmaceuticals Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Apellis Pharmaceuticals nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.08.19 | Apellis Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 30.07.18 | Apellis Pharmaceuticals Buy | B. Riley FBR | |
| 24.05.18 | Apellis Pharmaceuticals Overweight | Cantor Fitzgerald | |
| 12.04.18 | Apellis Pharmaceuticals Neutral | B. Riley FBR, Inc. | |
| 08.02.18 | Apellis Pharmaceuticals Buy | B. Riley FBR, Inc. |